---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-239687"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-10-18T23:59:59+00:00"
generated_at: "2026-05-30T12:51:15.506089+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors

## Summary
- Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.
- Errors: weighted average ordinary shares outstanding incorrectly used ending shares instead of weighted average.
- Restatement affects only IFRS-based financials in 2022 Annual Report; 2023 US GAAP financials not impacted.
- Company intends to file amendment to 2022 Annual Report as soon as practicable.

## SEC filing metadata
- accession: 0001193125-24-239687
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/0001193125-24-239687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/d894508d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-239687
- JSON: https://secwatch.observer/filing/0001193125-24-239687.json
- Plain text: https://secwatch.observer/filing/0001193125-24-239687.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.